121 related articles for article (PubMed ID: 37956707)
1. Role of MRPs transporters in pharmacokinetics and intestinal toxicity of irinotecan.
Du T; Luo T; Wang J; Sun R; Cai H
Food Chem Toxicol; 2023 Dec; 182():114171. PubMed ID: 37956707
[TBL] [Abstract][Full Text] [Related]
2. Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4.
Lee HJ; Choi CH
BMC Cancer; 2022 Apr; 22(1):446. PubMed ID: 35461219
[TBL] [Abstract][Full Text] [Related]
3. [Irinotecan pharmacokinetics].
Chabot GG; Robert J; Lokiec F; Canal P
Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
[TBL] [Abstract][Full Text] [Related]
4. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.
Horikawa M; Kato Y; Sugiyama Y
Pharm Res; 2002 Sep; 19(9):1345-53. PubMed ID: 12403072
[TBL] [Abstract][Full Text] [Related]
5. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
Chu XY; Kato Y; Ueda K; Suzuki H; Niinuma K; Tyson CA; Weizer V; Dabbs JE; Froehlich R; Green CE; Sugiyama Y
Cancer Res; 1998 Nov; 58(22):5137-43. PubMed ID: 9823324
[TBL] [Abstract][Full Text] [Related]
6. Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
Yokooji T; Kawabe Y; Mori N; Murakami T
J Pharm Pharmacol; 2013 Feb; 65(2):280-91. PubMed ID: 23278696
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: Critical role of gut Ugt.
Sun R; Zhu L; Li L; Song W; Gong X; Qi X; Wang Y; Ghose R; Gao S; Hu M; Liu Z
Toxicol Appl Pharmacol; 2020 Jul; 398():115032. PubMed ID: 32387182
[TBL] [Abstract][Full Text] [Related]
8. Effect of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) micelles on pharmacokinetics and intestinal toxicity of irinotecan hydrochloride: potential involvement of breast cancer resistance protein (ABCG2).
Guo S; Zhang X; Gan L; Zhu C; Gan Y
J Pharm Pharmacol; 2010 Aug; 62(8):973-84. PubMed ID: 20663031
[TBL] [Abstract][Full Text] [Related]
9. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
Chu XY; Kato Y; Niinuma K; Sudo KI; Hakusui H; Sugiyama Y
J Pharmacol Exp Ther; 1997 Apr; 281(1):304-14. PubMed ID: 9103511
[TBL] [Abstract][Full Text] [Related]
10. New approaches to prevent intestinal toxicity of irinotecan-based regimens.
Alimonti A; Gelibter A; Pavese I; Satta F; Cognetti F; Ferretti G; Rasio D; Vecchione A; Di Palma M
Cancer Treat Rev; 2004 Oct; 30(6):555-62. PubMed ID: 15325035
[TBL] [Abstract][Full Text] [Related]
11. Effect of hesperidin on the pharmacokinetics of CPT-11 and its active metabolite SN-38 by regulating hepatic Mrp2 in rats.
Wang X; Rao Z; Qin H; Zhang G; Ma Y; Jin Y; Han M; Shi A; Wang Y; Wu X
Biopharm Drug Dispos; 2016 Oct; 37(7):421-432. PubMed ID: 27510985
[TBL] [Abstract][Full Text] [Related]
12. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
Chu XY; Kato Y; Sugiyama Y
Cancer Res; 1997 May; 57(10):1934-8. PubMed ID: 9157988
[TBL] [Abstract][Full Text] [Related]
13. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
[TBL] [Abstract][Full Text] [Related]
14. Single Protein Encapsulated SN38 for Tumor-Targeting Treatment.
Yu CJ; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
Res Sq; 2023 Jul; ():. PubMed ID: 37546894
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
[TBL] [Abstract][Full Text] [Related]
16. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.
Vlaming ML; Teunissen SF; van de Steeg E; van Esch A; Wagenaar E; Brunsveld L; de Greef TF; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Mol Pharmacol; 2014 Mar; 85(3):520-30. PubMed ID: 24334255
[TBL] [Abstract][Full Text] [Related]
17. Novel Hydrophilic Camptothecin Derivatives Conjugated to Branched Glycerol Trimer Suppress Tumor Growth without Causing Diarrhea in Murine Xenograft Models of Human Lung Cancer.
Tsuchihashi Y; Abe S; Miyamoto L; Tsunematsu H; Izumi T; Hatano A; Okuno H; Yamane M; Yasuoka T; Ikeda Y; Tsuchiya K
Mol Pharm; 2020 Apr; 17(4):1049-1058. PubMed ID: 32068412
[TBL] [Abstract][Full Text] [Related]
18. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11).
Chen S; Yueh MF; Bigo C; Barbier O; Wang K; Karin M; Nguyen N; Tukey RH
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):19143-8. PubMed ID: 24191041
[TBL] [Abstract][Full Text] [Related]
19. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.
Horikawa M; Kato Y; Tyson CA; Sugiyama Y
Drug Metab Pharmacokinet; 2002; 17(1):23-33. PubMed ID: 15618649
[TBL] [Abstract][Full Text] [Related]
20. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer.
Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M
Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
